Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innovent Biologics ( (HK:1801) ) has provided an update.
Innovent Biologics reported a 40% year-on-year increase in product revenue for the third quarter of 2025, reaching over RMB3.3 billion. This growth was driven by the expansion of its oncology and general biomedicine product portfolios, including the successful market uptake of products like mazdutide and SINTBILO. The approval of mazdutide for type 2 diabetes by China’s National Medical Products Administration further strengthens Innovent’s market position, aligning with its vision to become a global premier biopharmaceutical company.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$110.62 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on oncology and general biomedicine, including cardiovascular, metabolism, autoimmune, and ophthalmology sectors. The company is committed to sustainable growth and global innovation, with a robust pipeline of 16 approved products and several others in various stages of clinical trials.
Average Trading Volume: 19,874,954
Technical Sentiment Signal: Buy
Current Market Cap: HK$145B
See more data about 1801 stock on TipRanks’ Stock Analysis page.